Portal Hypertension Recruiting Phase 2 Trials for Ambrisentan (DB06403)

Also known as: Hypertension Portal / Hypertension, Portal / Portal hypertensions

IndicationStatusPhase
DBCOND0029015 (Portal Hypertension)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03827200A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver CirrhosisTreatment